Longitudinal variance components models for systolic blood pressure, fitted using Gibbs sampling by Scurrah, Katrina J et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
BMC Genetics
Open Access Proceedings
Longitudinal variance components models for systolic blood 
pressure, fitted using Gibbs sampling
Katrina J Scurrah, Martin D Tobin and Paul R Burton*
Address: Institute of Genetics and Department of Epidemiology and Public Health, University of Leicester, 22-28 Princess Road, Leicester, LE1 6TP, 
United Kingdom
Email: Katrina J Scurrah - ks67@leicester.ac.uk; Martin D Tobin - mt47@leicester.ac.uk; Paul R Burton* - pb51@leicester.ac.uk
* Corresponding author    
Abstract
This paper describes an analysis of systolic blood pressure (SBP) in the Genetic Analysis Workshop
13 (GAW13) simulated data. The main aim was to assess evidence for both general and specific
genetic effects on the baseline blood pressure and on the rate of change (slope) of blood pressure
with time. Generalized linear mixed models were fitted using Gibbs sampling in WinBUGS, and the
additive polygenic random effects estimated using these models were then used as continuous
phenotypes in a variance components linkage analysis. The first-stage analysis provided evidence for
general genetic effects on both the baseline and slope of blood pressure, and the linkage analysis
found evidence of several genes, again for both baseline and slope.
Background
Longitudinal studies of families reduce measurement
error, provide increased power, and allow researchers to
assess genetic and environmental effects on both baseline
measurements of phenotypes and the rate of change of the
phenotype over time. However, care must be taken to use
an appropriate model that fully accounts for both the
intra-familial and the intra-individual correlation in the
repeated measurements. This paper describes such a
model, which is an extension of our previously described
generalized linear mixed models (GLMMs) for cross sec-
tional familial data [1,2], and applies this model to Repli-
cate 1 of the Genetic Analysis Workshop 13 (GAW13)
simulated data.
The aims of our analysis were three-fold: 1) to assess evi-
dence for genetic effects on the rate of increase of SBP with
age, as well as genetic effects on the blood pressure at any
given time, 2) to determine which of the available covari-
ates were associated with SBP, while correctly accounting
for the complex familial correlation structure, and 3) to
assess the performance of models for longitudinal familial
data when applied to realistic data simulated by groups
other than our own. Results of fitting GLMMs and vari-
ance components linkage models are presented and
discussed.
Methods
Data
We analyzed the repeated measurements of systolic blood
pressure (SBP) in the first replicate of the simulated
GAW13 data with missing values, including all 4692 indi-
viduals in all 330 pedigrees. Analyses were done blind to
the answers.
Each missing value of the covariates 'drink' (number of
drinks per week) and 'CPD' (number of cigarettes per day)
was replaced with the mean of the covariate for that indi-
vidual in the two observations surrounding the missing
observation, enabling us to increase the number of useful
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observations without excluding important covariates
from the model. The phenotypic component of the model
included 25,055 observations for 2851 individuals. These
observations all had non-missing values for SBP, height,
drink, and CPD.
Model
The models fitted in this analysis are extensions of our
previously described variance components models for
extended pedigrees with normal, binary, or censored sur-
vival phenotypes [1,2]. The original models are GLMMs
with components of variance due to additive polygenic
effects (σ2
A), common family environment (σ2
C), com-
mon sibling environment (σ2
Cs), and residual error (σ2
E).
The complex familial correlation structure is modelled
through the use of shared random effects for each variance
component. The model for the jth individual in the ith ped-
igree can be represented as:
µij = β0 + βTXij + Aij + Cij + Csij
yij ~ N(µij, σ2
E),
where yij is the observed phenotype, Xij is a matrix of
covariates,
Ai ~ N(0, VA), Ci ~ N(0, VC), Csi ~ N(0, VCs),
and the random effects for each family are sampled from
appropriate multivariate normal distributions with vari-
ance-covariance matrices (VA, VC, and VCs) parameterized
by  σ2
A,  σ2
C, and σ2
Cs, respectively, and structured as
described previously [1]. Individuals without phenotypic
data were used in generating the random effects but not in
the main model.
The extensions not only allow for repeated measures on
individuals, but use the extra information available to
assess evidence for genetic effects on the rate of change of
the outcome over time. At the kth observation for the jth
individual in the ith pedigree, the model can be expressed
as
µijk = β0 + βTXijk + Aij + Cij + Csij + ageijk × (βage + A.timeij +
C.timeij + Cs.timeij + E.timeij)
yijk ~ N(µijk, σ2
E),
where yijk is the observed phenotype, Xijk is a matrix of cov-
ariates, βage is the mean gradient of age (for all individu-
als), Ai ~ N(0, VA), Ci ~ N(0, VC), Csi ~ N(0, VCs), A.timei
~ N(0, VA.time), C.timei ~ N(0, VC.time), Cs.timei ~ N(0,
VCs.time), and E.timeij ~ N(0, σ2
E.time).
In this model time was measured using the covariate 'age'.
The random effects for the gradient of age, A.timeij,
C.timeij, Cs.timeij, and E.timeij, have a covariance struc-
ture equivalent to that described previously [1,2], with
each variance component replaced by its counterpart for
the gradient, so (for example) in this part of the model σ2
A
is represented by σ2
A.time. However, the variance compo-
nents for the intercept (σ2
A, σ2
C, σ2
Cs, and σ2
E) are inde-
pendent of the variance components for the gradient
(σ2
A.time, σ2
C.time, σ2
Cs.time, and σ2
E.time), and the estimated
random effects for each variance component for the inter-
cept are different from the estimated random effects for
each variance component for the gradient. All random
effects are constant across observations on the same indi-
vidual; they do not change over time. Just as the size of σ2
A
can indicate whether additive genetic effects influence the
outcome, the size of σ2
A.time can indicate whether additive
genetic effects influence the rate of change of the outcome
with time.
All covariates were centered before inclusion in the
model. The main model included the covariates male sex,
cohort, height, drink, CPD, and some models also
included BMI ((weight in kg)/(height in m)2) as a contin-
uous variable. To allow for a nonlinear increase in SBP
with age, quadratic and cubic age terms were also
included.
The models were fitted using Gibbs sampling in Win-
BUGS v1.3 [3]. Vague normal N(0, 1000) priors were
specified for fixed regression coefficients. Vague Pareto
(1,0.001) priors were specified on the precisions (inverses
of the variances) of all random effects; these were equiva-
lent to specifying uniform priors on the corresponding
variances. The priors for the intercept variance compo-
nents (and associated random effects) were independent
of the priors for the gradient variance components (and
associated random effects). Models were run for 20,000
iterations after a burn-in of 5000 iterations. Although the
model is Bayesian, the effect of each covariate was also
assessed using a pseudo-likelihood approach.
Blood pressure adjustment
The problem of how to model continuous SBP when
some individuals are on blood pressure treatment is com-
plex. As Cui et al. state, "the usual regression techniques
used to adjust for the effects of antihypertensive treatment
are inappropriate because they result in treated levels hav-
ing an average of zero residuals rather than the extremeBMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S25
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residuals they deserve, given their pretreatment pressures"
[4]. Since complex modelling of SBP was not the main
aim of this particular analysis, we chose a simple method
of adjustment, which involved adding a constant (10 mm
Hg) to each phenotype in which the individual was on
treatment, to reflect the 'true' SBP that might have been
observed if the individual had not been on treatment [4].
Linkage analysis
As described previously [1,5] the random effects due to
σ2
A (Aij, the sigma-squared A residuals or SSARs) can be
used as a continuous phenotype in a linkage analysis. The
SSARs for the gradient (A.timeij, the sigma-squared A time
residuals, or SSATRs) may also be used in such a way. The
estimated SSARs and SSATRs were used as continuous
phenotypes in a variance components linkage analysis
that was performed using MERLIN [6]. All 399 markers
were included.
Results
Variance components analysis
Results from fitting the longitudinal GLMM are shown in
Table 1. Means ('best estimates') and 95% credible inter-
vals are presented for each parameter. We deliberately
excluded certain intermediate phenotypes (such as cho-
lesterol) from the model even though they were clearly
related to SBP, because they may lie on the causal pathway
leading to high blood pressure and thus their inclusion in
the model may produce misleading results. Many inter-
mediate phenotypes also had few repeated measure-
ments, so their inclusion would have greatly reduced the
amount of available data. It is unclear whether BMI is an
intermediate phenotype, but models including and
excluding this covariate were very similar, and since meas-
urements were available at almost all time points, results
from the model which included BMI are presented in
Table 1.
The size of σ2
A.time (relative to the other variance compo-
nents for the gradient) suggests that genes strongly influ-
ence the rate of change of SBP with age, while nongenetic
influences due to shared familial or sibling environment
are much less important. The same is true of the variance
components for the intercept; genetic effects appear to
account for the most variation in SBP at the mean age.
The mean rate of change of SBP with each year was 0.54,
suggesting that for the average individual, SBP increases
by approximately 5 mm Hg every 10 years. A nonlinear
effect was also apparent, because the credible intervals for
both the quadratic and cubic terms excluded 0. The 'aver-
age curve' for the relationship between BP and age (not
included) showed an approximately linear relationship
throughout most of the age range. When the quadratic
and cubic terms were excluded most results changed little.
Table 1: Results from main GLMM
Parameter Mean 95% Credible Interval
Fixed effects
β0 134.4 (133.2, 135.5)
β.cohort2 -0.9846 (-1.694, -0.3023)
β.male -0.9899 (-1.959, -0.08858)
β.hgt 1.739 (-3.319, 7.014)
β.bmi 0.1429 (0.07583, 0.208)
β.drink 0.005914 (-0.014, 0.02612)
β.cpd 0.1621 (0.1505, 0.174)
β.age 0.5445 (0.5167, 0.5736)
β.age2A -0.002039 (-0.00248, -0.001599)
β.age3B -4.48 × 10-5 (-6.49 × 10-5, -2.48 × 10-5)
Variance components
σ2
A 213.9 (199.8, 228)
σ2
C 5.99 (0.389, 16.13)
σ2
Cs 8.476 (4.271, 13.53)
σ2
E 11.63 (11.4, 11.86)
σ2
A.time 0.1273 (0.1088, 0.1436)
σ2
C.time 0.007721 (1.83 × 10-4, 0.01722)
σ2
Cs.time 0.01449 (0.006833, 0.02293)
σ2
E.time 0.007635 (1.10 × 10-4, 0.01995)
AQuadratic term for age; B Cubic term for age.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S25
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Other covariates also appeared to influence SBP. Males
tended to have slightly lower SBP than females, and indi-
viduals from the second cohort tended to have slightly
lower SBP than those included in the first cohort. The
number of cigarettes smoked per day was also important,
with an increase in BP of approximately 1 mm Hg for
every six cigarettes. BMI was an important predictor of
SBP, while height and number of drinks per day appeared
to show little association with SBP.
Results changed little when σ2
E.time was excluded, when
σ2
C and  σ2
C.time were excluded, when σ2
Cs and  σ2
Cs.time
were excluded, and when the SBP adjustment (for those
on blood pressure treatment) was changed to +5 mm Hg
or +20 mm Hg (instead of +10 mm Hg).
Linkage results
Statistically significant linkage (LOD > 3, p < 0.00001)
was found for both the SSARs and the SSATRs as shown in
Table 2. The strongest results were for chromosome 21.
Several other markers had LOD scores between 2 and 3;
while these are not statistically significant at the genome-
wide level they are regarded as 'possibly linked' and are
also included in Table 2.
Discussion
Our results corresponded well with the answers provided.
The substantive conclusions of the variance components
analysis were all consistent with the simulation model.
However, in the linkage analysis, the SSARS appeared to
detect both baseline and slope genes better than the
SSATRs. Two simulated genes that affected SBP slope, as
well as several genes which indirectly affected SBP
through other phenotypes, were within 15 cM of our pos-
itive result on chromosome 21. A simulated gene on chro-
mosome 19 also indirectly affected SBP. A gene for SBP
slope was simulated on chromosome 15 (4 cM) and a
gene for baseline SBP was simulated on chromosome 5
(176 cM), both quite close to the locations we found.
Other genes that indirectly affected SBP were also nearby
on these two chromosomes. However, our results for
chromosome 4 and chromosome 6 were false positives.
Our methods have several advantages. They make full use
of the extra information contained in the repeated obser-
vations for each individual, without first requiring the
information to be summarized in some way. It is easy to
include extra covariates or candidate gene information.
They allow the inclusion of all pedigree members, without
requiring decomposition of the pedigrees into smaller
structures. We are currently working on extending the
GLMMs to incorporate linkage directly, and this provides
extra cohesion in these types of analysis. It also ensures
that uncertainty in the estimates of the random effects is
allowed for in the linkage analysis. However, the extra
complexity in the unified models means that they can take
considerably longer to fit.
Our methods had several features in common with others
presented at GAW13. In particular, MacGregor et al. [7]
and Yang et al. [8] used variance components models for
longitudinal data, although their models also incorpo-
rated variance components for a QTL effect and they used
maximum likelihood rather than MCMC fitting methods.
Since they both analyzed the real data set, our results can-
not directly be compared. Further comparisons of our
method with those used by other authors may be found in
the group summary paper by Gauderman et al. [9].
Conclusions
The results we obtained suggest that our extended vari-
ance components models perform well in practice. They
are relatively straightforward to fit, and produce useful
and biologically plausible results.
Table 2: Summary of linkage results
Chromosome Phenotype Marker Location LOD p-Value
LOD > 3
21 SSAR GATA188F04 40 cM 12.92 < 0.00001
21 SSATR GATA188F04 40 cM 5.10 < 0.00001
19 SSAR Mfd139 68 cM 3.88 0.00001
2 < LOD < 3
15 SSAR GATA81F03 5 cM 2.99 0.00010
6 SSAR SE30 9 cM 2.86 0.00014
5 SSAR GATA6E05 160 cM 2.36 0.0005
4 SSATR GATA107 146 cM 2.21 0.0007Publish with BioMed Central    and   every 
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